688526 Stock Overview
Focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Wuhan Keqian Biology Co.,Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥13.79 |
52 Week High | CN¥20.61 |
52 Week Low | CN¥11.00 |
Beta | 0.67 |
11 Month Change | 0.073% |
3 Month Change | 16.47% |
1 Year Change | -29.71% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -42.90% |
Recent News & Updates
Recent updates
Shareholder Returns
688526 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -5.1% | 1.0% | -0.9% |
1Y | -29.7% | -4.8% | 5.4% |
Return vs Industry: 688526 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 688526 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
688526 volatility | |
---|---|
688526 Average Weekly Movement | 7.9% |
Pharmaceuticals Industry Average Movement | 7.2% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 688526 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688526's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 903 | Mulin Chen | www.kqbio.com |
Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. It offers vaccines for swine, poultry, and pets, as well as diagnostic reagents. The company was incorporated in 2001 and is based in Wuhan, China.
Wuhan Keqian Biology Co.,Ltd Fundamentals Summary
688526 fundamental statistics | |
---|---|
Market cap | CN¥6.40b |
Earnings (TTM) | CN¥299.11m |
Revenue (TTM) | CN¥902.14m |
21.4x
P/E Ratio7.1x
P/S RatioIs 688526 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
688526 income statement (TTM) | |
---|---|
Revenue | CN¥902.14m |
Cost of Revenue | CN¥344.01m |
Gross Profit | CN¥558.13m |
Other Expenses | CN¥259.02m |
Earnings | CN¥299.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.64 |
Gross Margin | 61.87% |
Net Profit Margin | 33.16% |
Debt/Equity Ratio | 1.5% |
How did 688526 perform over the long term?
See historical performance and comparison